Home > Focus Areas > DLBCL Connect > Post
4yr
Distribution of chimeric antigen receptor-modified T cells against CD19 in B-cell malignancies
Source : https://link.springer.com/article/10.1186/s12885-021-07934-1
Background The unprecedented efficacy of chimeric antigen receptor T (CAR-T) cell immunotherapy of CD19+ B-cell malignancies has opened a new and useful way for the treatment of malignant tumors. Nonetheless, there are still formidable challenges in the field of CAR-T cell therapy, such as the biodistribution of CAR-T cells in vivo.
-
Mark Fesler4yrWe struggle with whether to proceed with CAR T cell therapy in lymphoma patients having achieved a CR. This is interesting data in a mouse model and suggests that the antigen is not necessary for expansion and persistence.